Ideaya Biosciences Inc
NASDAQ:IDYA
| Market Cap (Intraday) | 573.01M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $11.68 |
| 50-Day MA | $12.56 |
| 200-Day MA | $13.75 |
Ideaya Biosciences Inc Stock, NASDAQ:IDYA
7000 Shoreline Court, Suite 350, South San Francisco, California 94080-1945
United States of America
Phone: +1.650.443.6209
Number of Employees: 81
Description
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.